BOPW
LCTX icon

Brandywine Oak Private Wealth’s Lineage Cell Therapeutics LCTX Stock Holding History

Brandywine Oak Private Wealth’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed – – 440
2018
Q4 		$0 Buy
+500
New +$766 ﹤0.01% 718

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Brandywine Oak Private Wealth's LCTX Position: Q1 2019 in Review

Brandywine Oak Private Wealth sold out of Lineage Cell Therapeutics (LCTX) in Q1 2019, closing a stake of 500 shares.

Brandywine Oak Private Wealth first reported a position in LCTX in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 118 funds tracked by Wall St. Rank hold LCTX as of Q1 2019.

  • Brandywine Oak Private Wealth reported no remaining Lineage Cell Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Brandywine Oak Private Wealth sold 500 Lineage Cell Therapeutics shares in Q1 2019.
  • Brandywine Oak Private Wealth first reported a position in Lineage Cell Therapeutics in Q4 2018 and held it in 1 quarter.
  • Brandywine Oak Private Wealth's Lineage Cell Therapeutics position peaked at $0 in Q4 2018.
  • 118 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2019.

Based on Brandywine Oak Private Wealth's 13F filing for Q1 2019, filed 9 May 2019.